Multiple Sclerosis and Related Disorders

The benefits of immune reconstitution therapy in MS 1:28
The benefits of immune reconstitution therapy in MS
Celia Oreja-Guevara • 28 Oct 2022
Blood serum proteome correlates of MS disease progression: a 5-year longitudinal study 1:38
Blood serum proteome correlates of MS disease progression: a 5-year longitudinal study
Ferhan Qureshi • 26 Oct 2022
CNS resilience as a major determinant of outcome in MS 1:51
CNS resilience as a major determinant of outcome in MS
Adil Harroud • 27 Oct 2022
Validation of the MSDA test in plasma 1:18
Validation of the MSDA test in plasma
Ferhan Qureshi • 26 Oct 2022
Key updates and research focuses at ECTRIMS 2022 7:37
Key updates and research focuses at ECTRIMS 2022
Mar Tintoré • 4 Nov 2022
The impact of comorbidities on treatment-related decisions in MS 1:56
The impact of comorbidities on treatment-related decisions in MS
Helen Tremlett • 20 Oct 2022
Understanding inflammation and progression in multiple sclerosis 1:20
Understanding inflammation and progression in multiple sclerosis
Eva Kubala Havrdová • 27 Oct 2022
Current recommendations on MS treatment during pregnancy 1:46
Current recommendations on MS treatment during pregnancy
Eva Kubala Havrdová • 27 Oct 2022
Upcoming MRI biomarkers in multiple sclerosis 1:09
Upcoming MRI biomarkers in multiple sclerosis
Jaume Sastre-Garriga • 28 Oct 2022
Imaging techniques to monitor remyelination in MS 2:35
Imaging techniques to monitor remyelination in MS
Cristina Granziera • 28 Oct 2022
OCT-A: a diagnostic tool in multiple sclerosis 1:53
OCT-A: a diagnostic tool in multiple sclerosis
Celia Oreja-Guevara • 28 Oct 2022
Role of imaging biomarkers of myelin repair in the development of neuroprotective drugs 0:43
Role of imaging biomarkers of myelin repair in the development of neuroprotective drugs
Cristina Granziera • 28 Oct 2022
Reappraisal of the 2017 McDonald criteria for multiple sclerosis 3:00
Reappraisal of the 2017 McDonald criteria for multiple sclerosis
Jaume Sastre-Garriga • 28 Oct 2022
MS & MOGAD: differences in response to immunomodulatory therapies 2:01
MS & MOGAD: differences in response to immunomodulatory therapies
Hans Lassmann • 27 Oct 2022
Pregnancy planning: differences between counselling NMOSD and MS patients 2:26
Pregnancy planning: differences between counselling NMOSD and MS patients
Melinda Magyari • 28 Oct 2022
Implementation of novel imaging biomarkers in clinical practice 1:52
Implementation of novel imaging biomarkers in clinical practice
Jaume Sastre-Garriga • 28 Oct 2022
The content of VJNeurology is intended for healthcare professionals